ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN

被引：0
|
作者：
Fernandez-Barcelo, C. [1 ]
Abbas, I
Botella, X. [2 ]
Aguilo Domingo, M. [2 ]
Cots, F. [3 ]
Siles Cuesta, C. [3 ]
Arriola, E. [3 ]
Gas Lopez, M. E. [4 ]
Lopez Gomez, C. [4 ]
Juan-Vidal, O. [5 ]
Planellas, L. [6 ]
Lloansi, A. [6 ]
Sanchez, J. [1 ]
Reguart, N. [1 ]
Sampietro-Colom, L. [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Consorci Sanitari Terrassa, Terrassa, Spain
[3] Hosp Mar CIBERONC, Barcelona, Spain
[4] Hlth Res Inst Hosp La Fe, Valencia, Spain
[5] Hosp La Fe Valencia, Valencia, Spain
[6] Amgen SA, Barcelona, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD89
引用
收藏
页码：S521 / S521
页数：1
相关论文
共 50 条
  • [31] In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung Cancer
    Kato, Ryoji
    Solanki, Hitendra S.
    Ozakinci, Hilal
    Desai, Bina
    Gundlapalli, Harika
    Yang, Yu Chi
    Aronchik, Ida
    Singh, Mallika
    Johnson, Joseph
    Marusyk, Andriy
    Boyle, Theresa A.
    Haura, Eric B.
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1150 - 1162
  • [32] VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer
    Yang, Xuechao
    Zhang, Shu
    Yang, Yang
    Duan, Xiaoqun
    Li, Xiaochuan
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [33] WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Saito, Hitoshi
    Yamamori-Morita, Tomoko
    Nakao, Takehiro
    Liu, Jie
    Mori, Shunta
    Yagishita, Shigehiro
    Hamada, Akinobu
    Shinno, Yuki
    Yoshida, Tatsuya
    Horinouchi, Hidehito
    Ohe, Yuichiro
    Watanabe, Shun-Ichi
    Yatabe, Yasushi
    Kitai, Hidenori
    Konno, Satoshi
    Kobayashi, Susumu S.
    Ohashi, Akihiro
    CANCER LETTERS, 2025, 611
  • [34] KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models
    Rosen, Joshua C.
    Nhu-An Pham
    Li, Quan
    Cao, Pinjiang
    Hueniken, Katrina
    Koga, Takamasa
    Radulovich, Nikolina
    Koers, Alex
    Niedbala, Michael
    Ross, Sarah
    Sacher, Adrian
    Tsao, Ming-Sound
    CANCER RESEARCH, 2024, 84 (06)
  • [35] CONTINUATION MAINTENANCE FOR ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Okamoto, Isamu
    ANNALS OF ONCOLOGY, 2014, 25
  • [36] INDIVIDUALIZED CHEMOTHERAPY (CT) IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Obodnikov, Oleksandr O.
    Orlovsriy, Oleksiy A.
    Parshikov, Oleksandr V.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1280 - S1281
  • [37] Paclitaxel cisplatin in advanced non-small-cell lung cancer (NSCLC)
    Pirker, R
    Krajnik, G
    Zochbauer, S
    Malayeri, R
    Kneussl, M
    Huber, H
    ANNALS OF ONCOLOGY, 1995, 6 (08) : 833 - 835
  • [38] Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China
    Chai, Qingqing
    Shen, Yunjie
    Du, Jiangyang
    Zhu, Jun
    Wu, Bin
    IMMUNOTHERAPY, 2020, 12 (04) : 245 - 254
  • [39] Weight loss affects outcome in KrasG12C non-small cell lung cancer first line treated patients.
    Fancelli, Sara
    Caliman, Enrico
    Pillozzi, Serena
    Napolitano, Brunella
    Pieroni, Edoardo
    Mazzoni, Francesca
    Paglialunga, Luca
    Michelet, Marta Rita Gatta
    Roviello, Giandomenico
    Castiglione, Francesca
    Bartoli, Caterina
    Antonuzzo, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Efficacy and Safety of Icotinib in Advanced Non-Small-Cell Lung Cancer Patients Harboring Uncommon EGFR Mutation: a Retrospective Analysis
    Yuan, Xiaobin
    Wang, Yang
    Yang, Min
    Shen, Zhilin
    Chen, Hui
    He, Xiangbo
    Ma, Yongbin
    Ding, Lieming
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (01): : 46 - 53
12345